. "Oral, rat: LD₅₀ = >5 gm/kg. Amphotericin B overdoses can result in cardio-respiratory arrest."@en . . "AMPH-b"@en . . . . . . . . . . . . . . . . . . . . . . . . "Frank Sipos, \"Process for producing the methyl ester of amphotericin B.\" U.S. Patent US4035567, issued March, 1976."@en . . "Amphotericin B"@en . . . . . . "C-AmB"@en . . . . . . . "Highly bound (>90%) to plasma proteins."@en . . . . . . . . . . . . . . . . . . . . . "* 39 +/- 22 mL/hr/kg [febrile neutropenic cancer and bone marrow transplant patients receiving infusion of 1 mg/kg/day at Day 1] * 17 +/- 6 mL/hr/kg [febrile neutropenic cancer and bone marrow transplant patients receiving infusion of 1 mg/kg/day 3-20 days later] * 51 +/- 44 mL/hr/kg [febrile neutropenic cancer and bone marrow transplant patients receiving infusion of 2.5 mg/kg/day at Day 1] * 22 +/- 15 mL/hr/kg [febrile neutropenic cancer and bone marrow transplant patients receiving infusion of 2.5 mg/kg/day 3-20 days later] * 21 +/- 14 mL/hr/kg [febrile neutropenic cancer and bone marrow transplant patients receiving infusion of 5 mg/kg/day at Day 1] * 11 +/- 6 mL/hr/kg [febrile neutropenic cancer and bone marrow transplant patients receiving infusion of 5 mg/kg/day 3-20 days later]"@en . "Amphotericin B is fungistatic or fungicidal depending on the concentration obtained in body fluids and the susceptibility of the fungus. The drug acts by binding to sterols (ergosterol) in the cell membrane of susceptible fungi. This creates a transmembrane channel, and the resultant change in membrane permeability allowing leakage of intracellular components. Ergosterol, the principal sterol in the fungal cytoplasmic membrane, is the target site of action of amphotericin B and the azoles. Amphotericin B, a polyene, binds irreversibly to ergosterol, resulting in disruption of membrane integrity and ultimately cell death."@en . . "investigational"@en . "Liposomal amphotericin b"@en . " "@en . " "@en . "1397-89-3"@en . . . . "Used to treat potentially life threatening fungal infections."@en . . "approved"@en . . "Amphotericin B shows a high order of in vitro activity against many species of fungi. Histoplasma capsulatum, Coccidioides immitis, Candida species, Blastomyces dermatitidis, Rhodotorula, Cryptococcus neoformans, Sporothrix schenckii, Mucor mucedo, and Aspergillus fumigatus are all inhibited by concentrations of amphotericin B ranging from 0.03 to 1.0 mcg/mL in vitro. While Candida albicans is generally quite susceptible to amphotericin B, non-albicans species may be less susceptible. Pseudallescheria boydii and Fusarium sp. are often resistant to amphotericin B. The antibiotic is without effect on bacteria, rickettsiae, and viruses."@en . . "Bioavailability is 100% for intravenous infusion."@en . . . . . . . . . . . . . . . . . . . . . . . "Amphot\u00E9ricine B"@en . "Amphotericin B"@en . . "Various Fungus Species"@en . . "An elimination half-life of approximately 15 days follows an initial plasma half-life of about 24 hours."@en . . "Amphotericinum B"@en . . "Amfotericina B"@en . . . . . . .